BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OSE2101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OSE2101\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04884282-2663@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:OSE2101: Phase 2 readout est. (NCT04884282)
DESCRIPTION:OSE2101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Efficac
 y of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy
  in Metastatic Non-small-cell Lung Cancer Progressing After First-line Che
 mo-immunotherapy (Combi-TED)\nEstimated primary completion: 30 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ose2101#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04884282
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264673-2663@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:OSE2101: Phase 2 readout est. (NCT07264673)
DESCRIPTION:OSE2101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Rando
 mized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance
  Therapy in ctDNA Positive NSCL. The Cemited Study.\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ose2101#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07264673
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06472245-2663@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:OSE2101: Phase 3 readout est. (NCT06472245)
DESCRIPTION:OSE2101\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Trial o
 f Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung 
 Cancer and Secondary Resistance to Immune Checkpoint Inhibitor\nEstimated 
 primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ose2101#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06472245
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751798-2663@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:OSE2101: Phase 1/2 readout est. (NCT05751798)
DESCRIPTION:OSE2101\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Dose-
 finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Soli
 d Tumors or Lymphomas\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ose2101#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05751798
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
